Cell therapy for COPD
Part of Lungs & breathing clinical trials.
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have been diagnosed with COPD by a doctor.
- You can walk about 150 to 600 meters in 6 minutes.
- You have not been hospitalized for a COPD flare-up more than 4 times in the last year.
- You do not have pneumonia or a recent COVID-19 infection.
- You have never needed a breathing machine (ventilator).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding umbilical cord stem cells to standard triple therapy can help people with Group E COPD. It aims to see if this approach improves lung function and quality of life.
This trial tests whether transplanting a patient's own lung stem cells can improve lung function in people with chronic obstructive pulmonary disease (COPD). It aims to see if this treatment is safe and helps repair damaged lung tissue.
This trial tests whether a special stem cell treatment can help people with moderate to severe COPD when regular medicines are not working well. The treatment may reduce breathing problems and improve quality of life.
This study tests an experimental medication for chronic obstructive pulmonary disease (COPD) in two parts: first in healthy volunteers, then in people with COPD. It aims to see if the drug is safe and how well it works.
This trial tests a new cell-based therapy for people with IPF, a lung condition that causes scarring and breathing problems. The goal is to see if the treatment can help slow the disease and improve breathing ability.
This phase 3 trial tests a new cell-based treatment (REGEND001) for people with moderate to severe COPD, especially those with emphysema. The treatment aims to repair damaged lung tissue, potentially improving breathing and quality of life.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.